EAGAN, Minn., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera’s novel phase 2 cancer immunotherapy. These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors. The high profile late-breaking session of the AACR-NCI-EORTC will feature initial translational research from Biothera’s ongoing phase 2 clinical study combining Imprime PGG and Merck’s anti-PD-1 antibody, Keytruda®, for the treatment of biomarker-positive patients with triple negative breast cancer or metastatic melanoma.
American Association of Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, Boston, MA, October 1-4, 2017
| Session Date & Time | Monday, October 2, 2017, 5:30pm to 7:30pm ET |
| Session | Poster Session A |
| Presentation Title | Imprime PGG, a soluble yeast β-glucan PAMP, synergizes with anti-PD-1 antibody to enhance CD8 T cell anti-tumor immunity |
| Session Location | Boston Marriott Copley Place, Back Bay |
| Abstract Number | A18 |
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, October 26-30, 2017
| Session Date & Time | Saturday, October 28, 2017, 12:30pm-4:00pm, ET |
| Session | Immune Modulators, Late-Breaking Poster Session A |
| Presentation Title | Imprime PGG (Imprime) plus pembrolizumab (PEM): a phase 2 immunotherapeutic combination in patients selected for an Imprime-specific biomarker |
| Session Location | Hall E, Pennsylvania Convention Center |
| Abstract Number | LB-A31 |
| Session Date & Time | Sunday, October 29, 2017, 12:30pm to 4:00pm ET |
| Session Category | Immune Modulators |
| Session Title | Poster Session B |
| Presentation Title | Imprime PGG, a soluble yeast β-glucan PAMP, activates both innate and adaptive immune effector cells, resulting in enhanced antitumor responses that synergize with anti-PD-1 antibody therapy |
| Session Location | Hall E, Pennsylvania Convention Center |
| Poster Board Number | 9 |
| Abstract Number | B009 |
Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting, National Harbor, MD, November 8-12, 2017
| Session Date & Time | Saturday, November 11, 2017, 12:30 – 2pm and 6:30 – 8pm ET |
| Presentation Titles: | Increasing the levels of anti-beta glucan antibodies by administration of intravenous immunoglobulin (IVIG) induces immunopharmacodynamic (IPD) responses of a novel immunotherapeutic Imprime PGG |
| Session Location: | Gaylord National Hotel & Convention Center, Prince George’s Exhibition Hall DE |
| Abstract Number: | P74 |
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Contact:
David Walsh
Biothera Pharmaceuticals, Inc.
651-256-4606
dwalsh@biothera.com